| | Author | Fractional dose | Total dose | Survival parameters | Follow-up |
| | Sorbe et al. [9] | 3–8 Gy/5 mm | 18–24 Gy | LRR: 2,6%, DM: 1,3%,
VR: 1,2% | - | | Weiss et al. [10] | 4,6–4,9 Gy/5 mm
(7 Gy/surface) | 13,8–14,7 Gy | Pelvic relapse 5,7%, vaginal stump relapse 1,6%, local and distance relapse 2,5%, DM: 1,6%, 5-RFS 74% in MR group and 94% in HR group | 25,6 m | | Chadha et al. [11] | 7 Gy/5 mm | 21 Gy | VR: 0%, 5-OS: 93%, 5-DFS: 87% | 30 m | | Anderson et al. [12] | 5 Gy/5 mm | 15 Gy | Pelvic relapse 3%, vaginal relapse 1%, 5-OS 84%, 5-DFS 93%, | - | | Alektiar et al. [13] | 6-7 Gy/5 mm | 18–21 Gy | 5-OS 93%, 5-DFS 97% | 48 m | | McCloskey et al. [14] | 7 Gy/5 mm | 21 Gy | Local relapse 3,4%, vaginal relapse 1,1%, vaginal and pelvic relapse 1,1%, pelvic relapse 1,1% | 52 m | | Ríos et al. [15] | 4 Gy/5 mm | 20 Gy | Vaginal stump relapse 0%, relapse in lower part of vagina 1,7%, DM 6,7% | 46,7 m | | PORTEC-2 [16] | 7 Gy/5 mm | 21 Gy | 5-VR: 1,8%, 5-LRR: 5,1%, 5-OS 84,8%, 5-DFS 82,7% | 45 m | | Lin et al. [17] | 7 Gy/5 mm | 21 Gy | 5-OS 86%, 5-DFS 89% | 55 m | | Atahan et al. [18] | 5,5 Gy/5 mm | 27,5 Gy | VR: 1,6%, DM 3,2%, 5-OS 96%, 5-DFS 93% | 48 m | | Solhjem et al. [19] | 7 Gy/5 mm | 21 Gy | No local relapses | 23 m | | Cengiz et al. [20] | 7 Gy/5 mm | 21 Gy | 5-OS 85%, 5-DFS 92%, 5-LC 95% | 54 m | | Rittenberg et al. [21] | 5,6 Gy/5 mm | 16,8 Gy | VR: 2,3% 2-OS 97%, 5-OS 95% | 32 m | | Horowitz et al. [22] | 7 Gy/5 mm | 21 Gy | All relapse: 8,5%, vaginal relapses: 2%, 5-OS 87%, 5-DFS 90% | 65 m | | Rovirosa et al. [23] | 5-6 Gy/5 mm | 20–24 Gy | No vaginal relapses | 75 m | | Rovirosa et al. [23] | 4–6 Gy/5 mm | 24–36 Gy | No vaginal relapses | 88 m | | Rovirosa et al. [24] | 6 Gy/5 mm | 18 Gy | No vaginal relapses | 41 m | | Townamchai et al. [25] | 4 Gy/surface | 24 Gy | Vaginal relapses 1,2%, para-aortic nodes relapses 1,9%, DM 1,2% | 22,8 m |
|
|
